Outcomes of Six-Dose High-Dose Cytarabine as a Salvage Regimen for Patients with Relapsed/Refractory Acute Myeloid Leukemia

Anders, Brandi; Veltri, Lauren; Kanate, Abraham S.; Shillingburg, Alexandra; Shah, Nilay; Craig, Michael; Cumpston, Aaron

doi:10.1155/2017/6464972

Cited by 5 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite an initial response to treatment, AML may progress rapidly and disease relapse is common [3]. Relapsed/refractory (R/R) AML is associated with a poor prognosis [4].…”

Section: Introductionmentioning

confidence: 99%

Economic and Clinical Burden of Relapsed and/or Refractory Active Treatment Episodes in Patients with Acute Myeloid Leukemia (AML) in the USA: A Retrospective Analysis of a Commercial Payer Database

et al. 2019

View full text Add to dashboard Cite

This retrospective study estimated healthcare resource use (HRU), symptoms and toxicities (SxTox), and costs in relapsed/refractory (R/R) patients with acute myeloid leukemia (AML), stratified by hematopoietic stem cell transplantation (HSCT) status. Claims data were used to identify adult patients with AML diagnoses from 1 January 2008 to 31 March 2016 in the USA. Patients were considered R/R if they had an AML relapse ICD-9 code (205.02) or a line of therapy consistent with R/R disease. The final R/R sample (N = 707) included 476 patients with and 231 patients without HSCT. The mean total episode cost (from relapse date to death or end of study period) for all patients was $439,104 (with HSCT $524,595 and without HSCT $263,310). Inpatient visits accounted for the greatest cost component (mean $308,978) followed by intensive care unit stays (mean $221,537), non-clinician (e.g., lab tests) visits (mean $30,909), and outpatient pharmacy utilization (mean $24,640). Patients with HSCT appeared to have longer episodes of care compared with patients without HSCT (16.8 vs 11.1 months), perhaps reflecting longer survival for HSCT patients. Mean number of visits within each category and their associated costs appeared to be higher in patients with HSCT compared with patients without HSCT. Patients with HSCT appeared to experience more SxTox compared with patients without HSCT across all categories. Results of the current study suggest that there is a substantial HRU and cost burden on R/R AML patients in the USA receiving active treatments. More effective therapies with improved tolerability would meet this tremendous unmet need in the R/R AML population.Funding: Astellas Pharma, Inc.

show abstract

“…Despite an initial response to treatment, AML may progress rapidly and disease relapse is common [3]. Relapsed/refractory (R/R) AML is associated with a poor prognosis [4].…”

Section: Introductionmentioning

confidence: 99%

Economic and Clinical Burden of Relapsed and/or Refractory Active Treatment Episodes in Patients with Acute Myeloid Leukemia (AML) in the USA: A Retrospective Analysis of a Commercial Payer Database

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Intensive chemotherapy for curative treatment of all non-M3 AML subtypes (∼90%) includes cytarabine (ara-C) as a single agent or ara-C in combination with a variable anthracycline and/or kinase inhibitor . After more than 50 years of widespread clinical use, the mechanisms responsible for ara-C’s selective killing of white blood cells remain poorly understood.…”

mentioning

confidence: 99%

RNA Targeting in Acute Myeloid Leukemia

Messikommer

Seipel

Byrne

et al. 2020

ACS Pharmacol. Transl. Sci.

View full text Add to dashboard Cite

Nucleosides and their analogues constitute an essential family of anticancer drugs. DNA has been the presumptive target of the front-line prodrug for acute myeloid leukemia (AML), cytarabine (ara-C), since the 1980s. Here, the biomolecular targeting of ara-C was evaluated in primary white blood cells using the ara-C mimic “AzC” and azide–alkyne “click” reactions. Fluorescent staining and microscopy revealed that metabolic incorporation of AzC into primary white blood cells was unexpectedly enhanced by the DNA polymerase inhibitor aphidicholine. According to RNaseH digestion and pull-down-and-release experiments, AzC was incorporated into short RNA fragments bound to DNA in peripheral blood monocytes (PBMCs) collected from all six healthy human donors tested. Samples from 22 AML patients (French–American–British classes M4 and M5) exhibited much more heterogeneity, with 27% incorporating AzC into RNA and 55% into DNA. The overall survival of AML patients whose samples incorporated AzC into RNA was approximately 3-fold higher as compared to that of the DNA cohort (p ≤ 0.056, χ2 = 3.65). These results suggest that the RNA primers of DNA synthesis are clinically favorable targets of ara-C, and that variable incorporation of nucleoside drugs into DNA versus RNA may enable future patient stratification into treatment-specific subgroups.

show abstract

Toxicity and outcome of adults with acute myeloid leukemia receiving consolidation with high-dose cytarabine

Lopes,

Nucci,

Portugal

2024

Hematology, Transfusion and Cell Therapy

View full text Add to dashboard Cite

Outcomes of Six-Dose High-Dose Cytarabine as a Salvage Regimen for Patients with Relapsed/Refractory Acute Myeloid Leukemia

Cited by 5 publications

References 19 publications

Economic and Clinical Burden of Relapsed and/or Refractory Active Treatment Episodes in Patients with Acute Myeloid Leukemia (AML) in the USA: A Retrospective Analysis of a Commercial Payer Database

Economic and Clinical Burden of Relapsed and/or Refractory Active Treatment Episodes in Patients with Acute Myeloid Leukemia (AML) in the USA: A Retrospective Analysis of a Commercial Payer Database

RNA Targeting in Acute Myeloid Leukemia

Toxicity and outcome of adults with acute myeloid leukemia receiving consolidation with high-dose cytarabine

Contact Info

Product

Resources

About